Active Filter(s):
Details:
CPI-613® (devimistat) is a first-in-class clinical lead compound of Cornerstone, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells.
Lead Product(s): Devimistat,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Recipient: Cornerstone Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022